Navigation Links
Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
Date:12/23/2009

mportant class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin for weight management, has completed a pivotal Phase 3 clinical trial program. Arena submitted lorcaserin's New Drug Application to the FDA in December 2009.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the development, therapeutic indication and use, tolerability, safety, and efficacy of MK-1903; the discontinuation of Arena's collaboration with Merck; future collaborative activities; the regulatory approval of lorcaserin; and Arena's focus, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, regulatory authorities may not accept Arena's NDA submission; regulatory authorities may not find data from Arena's clinical trials and studies sufficient for regulatory approval; the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its p
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medizone International Takes Aim at the Bioterrorism Countermeasures Arena
2. Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
3. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
6. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
8. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
9. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
11. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
(Date:12/13/2014)... - MaRS and Virgin Unite Canada, the non-profit foundation of ... to support Canadian entrepreneurs tackling social and environmental challenges. Today, ... the MaRS Centre to announce the new partnership, which includes ... fund has $1 million in seed capital provided by Virgin ... Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... Draws Participants From A Broad Range of Industries Despite ... edition of InformexUSA officially opened its exhibition floors Wednesday ... show traffic in 2008. The week long exhibition & ... in North America, is featuring an expanded program to ...
... Mass., Jan. 29 Repligen Corporation (Nasdaq: ... Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... 2009 at 10:00 a.m. EST, to report third quarter ... quarterly update of the Company.This call is being webcast ...
... 29, 2009 Senomyx, Inc. (Nasdaq: SNMX ) ... fiscal year ending December 31, 2008 on Thursday, February 12, ... The Company will also host a conference call and live ... Time) that same day. During the call, Senomyx,s management ...
Cached Biology Technology:InformexUSA 2009 Opens to Strong Attendance 2InformexUSA 2009 Opens to Strong Attendance 3InformexUSA 2009 Opens to Strong Attendance 4Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results 2Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results 3SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... rich in omega-3 fatty acids can inhibit growth of breast ... from the University of Guelph. The study, published recently ... to be the first to provide unequivocal evidence that omega-3s ... Ma, a professor in Guelph,s Department of Human Health and ...
... Washington, DC The Entomological Society of America (ESA) ... today a new partnership that will provide ESA members ... policy debates. The ESA is the ... scientific needs of entomologists and individuals in related disciplines. ...
... of Southampton have identified the molecular system that ... brain during neurodegenerative diseases. An important aspect ... Huntington,s or prion disease, is the generation of ... Results from the study open new avenues ...
Cached Biology News:Omega-3s inhibit breast cancer tumor growth, study finds 2Entomological Society of America launches science policy program 2Scientists identify molecular system that could help develop treatments for Alzheimer's disease 2